|
|
Jamie Cavanagh, St. Bartholomew's Hospital, London, UK
|
|
Understanding VELCADE as a Subcutaneous (SQ) Injection
New! Tip Card on Subcutaneous VELCADE
FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Patients Personifying Progress:
Mary Ming-Mosely
Subcutaneous VELCADE® Site
VELCADE® Downloadable Resources
Open Velcade® (bortezomib) Trials
Eastern Cooperative Oncology Group Clinical Trial:E1A05
Understanding VELCADE® (bortezomib) for Injection
Subcutaneous VELCADE® Approved in the EU for the Treatment of Multiple Myeloma
VELCADE® Webcasts from the 2012 American Society of Clinical Oncology (ASCO) Meeting
VELCADE® Webcasts from the 2011 American Society of Hematology (ASH) Annual Meeting
Millennium's VELCADE Reimbursement Assistance Program
Millennium: The Takeda Oncology Company's Web Site
Archived VELCADE Webcasts
General Information
|
|
|
Two short videos explaining what you need to know about VELCADE SQ. |
|
|
|
|
|
Study met primary efficacy endpoint of non-inferiority between subcutaneous and intravenous administration.
Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy.
|
|
|
|
|
Two months ago, I started on VELCADE subcutaneous. It’s just a shot. I don’t
have to wait for an IV. It’s just in-and-out. VELCADE has kept me going and
feeling well enough to live my life. |
|
|
|
|
The US Food and Drug Administration (FDA) has approved subcutaneous VELCADE for the treatment of multiple myeloma. This approval was based on a large, international clinical trial that studied VELCADE injected under the skin compared with VELCADE injected into a vein. The 222 patients in this study had been treated for their myeloma and relapsed. |
|
|
|
|
Information for patients and clinicans on indications and usage. |
|
Clinical Trials
|
|
|
|
Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade®) & Lenalidomide (Revlimid®) - Dexamethasone (VRD) versus Bortezomib (Velcade®:) - Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen |
|
Publications
|
|
|
Part of the IMF's Understanding series, this booklet covers the basics, including: What is VELCADE®? How does it work? How is VELCADE® given? How is it used in clinical practice today? What are the side effects? |
|
News
|
|
|
|
The approval is based on data from a Phase III study demonstrating that subcutaneous administration of bortezomib is equally effective as intravenous bortezomib but is associated with a significant reduction in the frequency and severity of side effects. |
|
Webcasts About Velcade
|
|
|
The experts talk about VELCADE® in clinical trials, as frontline therapy and for relapsed patients, alone and in trials with various other agents in nine webcasts. |
|
Links
|
|
|
Program is available to patients, physicians, and caregivers to provide assistance regarding reimbursement issues related to the use of VELCADE® (bortezomib) for Injection. |
|
Archive
|
|
|
Webcasts on VELCADE research from past medical meetings. |
|
|
|
|
|
Past articles and press releases about VELCADE. |
|
|
back
print
related articles
Be the first to comment